| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| K Strecker, J P Schneider, H Barthel, W Hermann, F Wegner, A Wagner, J Schwarz, O Sabri, C Zimme. Profound midbrain atrophy in patients with Wilson's disease and neurological symptoms? Journal of neurology. vol 253. issue 8. 2006-10-26. PMID:16607473. |
data were correlated to the severity of neurological symptoms and the integrity of dopaminergic neurons measured via dopamine transporter binding. |
2006-10-26 |
2023-08-12 |
Not clear |
| Kristen S L Lam, Michael G Aman, L Eugene Arnol. Neurochemical correlates of autistic disorder: a review of the literature. Research in developmental disabilities. vol 27. issue 3. 2006-10-25. PMID:16002261. |
the role of dopaminergic functioning has not been compelling thus far, though conflicting findings on central dopamine turnover require further study. |
2006-10-25 |
2023-08-12 |
human |
| Miguel Garzón, Virginia M Picke. Subcellular distribution of M2 muscarinic receptors in relation to dopaminergic neurons of the rat ventral tegmental area. The Journal of comparative neurology. vol 498. issue 6. 2006-10-25. PMID:16927256. |
we sought to determine the functionally relevant sites for m2r activation in relation to vta dopaminergic neurons by examining the electron microscopic immunolabeling of m2r and the dopamine transporter (dat) in the vta of rat brain. |
2006-10-25 |
2023-08-12 |
rat |
| Manuchair Ebadi, Sushil Sharm. Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease. Experimental biology and medicine (Maywood, N.J.). vol 231. issue 9. 2006-10-25. PMID:17018883. |
a progressive nigrostriatal dopaminergic neurodegeneration in weaver mutant (wv/wv) mice was associated with enhanced nitrite ion synthesis, metallothionein down-regulation, and significantly reduced dopamine synthesis and 18f-dopa uptake as determined by high-resolution micropositron emission tomography neuroimaging. |
2006-10-25 |
2023-08-12 |
mouse |
| John C Morgan, Kapil D Seth. Rotigotine for the treatment of Parkinson's disease. Expert review of neurotherapeutics. vol 6. issue 9. 2006-10-24. PMID:17009915. |
dopaminergic therapies, including levodopa and dopamine agonists, are the mainstays of therapy in parkinson's disease. |
2006-10-24 |
2023-08-12 |
Not clear |
| John C Morgan, Kapil D Seth. Rotigotine for the treatment of Parkinson's disease. Expert review of neurotherapeutics. vol 6. issue 9. 2006-10-24. PMID:17009915. |
with the exception of the injectable short-acting dopamine agonist apomorphine, there is no other widely available non-oral dopaminergic therapy. |
2006-10-24 |
2023-08-12 |
Not clear |
| Masato Asanuma, Ikuko Miyazak. Nonsteroidal anti-inflammatory drugs in Parkinson's disease: possible involvement of quinone formation. Expert review of neurotherapeutics. vol 6. issue 9. 2006-10-24. PMID:17009919. |
the neurotoxicity of dopamine quinones, or dopa quinones, has recently received attention as a dopaminergic neuron-specific oxidative stress that is known to play a role in the pathogenesis of parkinson's disease and neurotoxin-induced parkinsonism. |
2006-10-24 |
2023-08-12 |
Not clear |
| W J Schmidt, M Ala. Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD). Journal of neural transmission. Supplementum. issue 70. 2006-10-24. PMID:17017541. |
evidence that rotenone-induced neurodegeneration spreads beyond the dopaminergic system is not contradictory given that, according to the new staging studies, also degeneration in pd is not confined to dopamine neurons. |
2006-10-24 |
2023-08-12 |
rat |
| R M Kostrzewa, J P Kostrzewa, R Brus, R A Kostrzewa, P Nowa. Proposed animal model of severe Parkinson's disease: neonatal 6-hydroxydopamine lesion of dopaminergic innervation of striatum. Journal of neural transmission. Supplementum. issue 70. 2006-10-24. PMID:17017542. |
rats lesioned shortly after birth with 6-hydroxydopamine are posed as a near-ideal model of severe parkinson's disease, because of the non-lethality of the procedure, near-total destruction of nigrostriatal dopaminergic fibers, near-total dopamine (da)-denervation of striatum, reproducibility of effect, and relative absence of overt behavioral effects--there is no aphasia, no adipsia, and no change in motor activity. |
2006-10-24 |
2023-08-12 |
rat |
| S Fah. A new look at levodopa based on the ELLDOPA study. Journal of neural transmission. Supplementum. issue 70. 2006-10-24. PMID:17017562. |
when it was recognized that dopamine, itself, might be a factor leading to the death of dopaminergic neurons through its contributing to the formation of oxyradicals, a new concern arose, namely that levodopa, through its conversion to brain dopamine, might add to the existing oxidative stress and possibly enhance neurodegeneration of dopaminergic neurons. |
2006-10-24 |
2023-08-12 |
Not clear |
| Bin Li. Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease. The AAPS journal. vol 8. issue 3. 2006-10-24. PMID:17025278. |
parkinson's disease (pd) is a debilitating movement disorder resulting from a progressive degeneration of the nigrostriatal dopaminergic pathway and depletion of neurotransmitter dopamine in the striatum. |
2006-10-24 |
2023-08-12 |
Not clear |
| Concepció Marin, Esther Aguilar, José A Obes. Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats. Movement disorders : official journal of the Movement Disorder Society. vol 21. issue 5. 2006-10-18. PMID:16437585. |
long-acting agents producing continuous dopaminergic stimulation are less likely to prime for dyskinesia than short-acting drugs that produce pulsatile stimulation of dopamine receptors. |
2006-10-18 |
2023-08-12 |
rat |
| Christian Pifl, Oleh Hornykiewic. Dopamine turnover is upregulated in the caudate/putamen of asymptomatic MPTP-treated rhesus monkeys. Neurochemistry international. vol 49. issue 5. 2006-10-18. PMID:16698121. |
in parkinson's disease (pd) and experimental parkinsonism, losses of up to 60% and 80%, respectively, of dopaminergic neurons in substantia nigra, and dopamine (da) in striatum remain asymptomatic. |
2006-10-18 |
2023-08-12 |
monkey |
| Robert A Hause. Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias. Geriatrics. vol 61. issue 9. 2006-10-10. PMID:16989543. |
dopamine agonists also provide more continuous dopaminergic stimulation but are associated with a greater likelihood of hallucinations and confusion, especially in the elderly. |
2006-10-10 |
2023-08-12 |
Not clear |
| Rui Li, Ning Peng, Xu-Ping Li, Wei-Dong L. (-)-Epigallocatechin gallate regulates dopamine transporter internalization via protein kinase C-dependent pathway. Brain research. vol 1097. issue 1. 2006-10-06. PMID:16733047. |
dopamine transporter (dat) provides not only an integral component of dopaminergic neurotransmission but also a molecular gateway for the accumulation of some neurotoxins such as 1-methyl-4-phenylpyridinium (mpp(+)), a metabolite of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (mptp). |
2006-10-06 |
2023-08-12 |
Not clear |
| Robert E Sorge, Jane Stewar. The effects of long-term chronic buprenorphine treatment on the locomotor and nucleus accumbens dopamine response to acute heroin and cocaine in rats. Pharmacology, biochemistry, and behavior. vol 84. issue 2. 2006-10-05. PMID:16806444. |
using in vivo microdialysis we found that both the suppression of the dopaminergic response in the nucleus accumbens to heroin and the potentiation to cocaine seen early in treatment diminished over the 26-27 days, whereas basal dopamine levels remained elevated throughout. |
2006-10-05 |
2023-08-12 |
rat |
| Jason R Richardson, W Michael Caudle, Minzheng Wang, E Danielle Dean, Kurt D Pennell, Gary W Mille. Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. vol 20. issue 10. 2006-10-05. PMID:16809432. |
these data suggest that developmental exposure to dieldrin leads to persistent alterations of the developing dopaminergic system and that these alterations induce a "silent" state of dopamine dysfunction, thereby rendering dopamine neurons more vulnerable later in life. |
2006-10-05 |
2023-08-12 |
mouse |
| O von Bohlen Und Halbac. Modeling neurodegenerative diseases in vivo review. Neuro-degenerative diseases. vol 2. issue 6. 2006-10-04. PMID:16909014. |
on the morphological and anatomical level, pd is characterized by massive degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to a severe loss of striatal dopaminergic fibers and to a massive reduction of dopamine levels in the striatum. |
2006-10-04 |
2023-08-12 |
monkey |
| Keith N Darrow, Emmanuel J Simons, Leslie Dodds, M Charles Liberma. Dopaminergic innervation of the mouse inner ear: evidence for a separate cytochemical group of cochlear efferent fibers. The Journal of comparative neurology. vol 498. issue 3. 2006-10-03. PMID:16871528. |
immunostaining mouse cochleas for tyrosine hydroxylase (th) and dopamine beta-hydroxylase suggests that there is a rich adrenergic innervation throughout the auditory nerve trunk and a small dopaminergic innervation of the sensory cell areas. |
2006-10-03 |
2023-08-12 |
mouse |
| Akhmad Kharis Nugroho, Stefan G Romeijn, Raphaël Zwier, Jan B de Vries, Durk Dijkstra, Håkan Wikström, Oscar Della-Pasqua, Meindert Danhof, Joke A Bouwstr. Pharmacokinetics and pharmacodynamics analysis of transdermal iontophoresis of 5-OH-DPAT in rats: in vitro-in vivo correlation. Journal of pharmaceutical sciences. vol 95. issue 7. 2006-09-29. PMID:16732562. |
pharmacokinetics and dopaminergic effect of dopamine agonist 5-oh-dpat in vivo were determined following transdermal iontophoresis in rats based on drug concentration in plasma (c(p)) and dopamine levels in striatum (c(da)). |
2006-09-29 |
2023-08-12 |
rat |